A bill to amend the Internal Revenue Code of 1986 to add meningococcal vaccines to the list of taxable vaccines for purposes of the Vaccine Injury Compensation Trust Fund.

S. 294, S. 1008, S.769, S.1255, S.785, Global Climate Change S. 556 Clean Air Convention on Biological Diversity & Cartagena Protocol on Biosafety H.R. 4591, Persistent Organic Pollutant Treaty; Montreal Protocol and Superfund

Client expense: $820,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Bureau of Engraving & Printing, Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS), Transportation Security Administration (TSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR)

Vaccine excise tax covering newly recommended vaccines under the Vaccine Injury Compensation Program; S. 1008, H.R. 5970

Client expense: Not reported · Firm income: $100,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE

S. 96: A bill to target Federal funding for research and development, to amend section 1928 of the Social Security Act to encourage the production of influenza vaccines by eliminating the price cap applicable to the purchase of such vaccines under contracts entered into by the Secretary of Health and Human Services, to amend the Internal Revenue Code of 1986 to establish a tax credit to encourage vaccine production capacity, and for other purposes. Lobbied for the interests of the vaccine industry.H.R. 628, H.R. 813: To amend the Public Health Service Act to provide for an influenza vaccine awareness campaign, ensure a sufficient influenza vaccine supply, and prepare for an influenza pandemic or epidemic, to amend the Internal Revenue Code of 1986 to encourage vaccing production capacity, and for other purposes. Lobbied for the interests of the vaccine industry. S. 375: A bill to amend the Public Health Service Act to provide for an influenza vaccine awareness campaign, ensure a sufficient influenza vaccine supply, and prepare for an influenza pandemic or epidemic, to amend the Internal Revenue Code of 1986 to encourage vaccine production capacity, and for other purposes. Lobbied for the interests of the vaccine industry. S. 375, H.R. 628, H.R. 813: A bill to amend the Public Health Service Act to provide for an influenza vaccine awareness campaign, ensure a sufficient influenza vaccine supply, and prepare for an influenza pandemic or epidemic, to amend the Internal Revenue Code of 1986 to encourage vaccine production capacity, and for other purposes. Lobbied for incentives for the vaccine industry. S. 627: A bill to amend the Internal Revenue Code of 1986 to permanently extend the research credit, to increase the rates of the alternative incremental credit, and to provide an alternative simplified credit for qualified research expenses. Lobbied for the R & D Tax credit. H.R. 1650: To amend the Internal Revenue Code of 1986 to allow tax credits to holders of stem cell research bonds. Lobbied for the R & D Tax credit. H.R. 1736: To amend the Internal Revenue Code of 1986 to permanently extend the research credit, to increase the rates of the alternative incremental credit, and to provide an alternative simplified credit for qualified research expenses. Lobbied for the R & D Tax credit. H.R. 2943, S. 1263: To amend the Small Business Act to establish eligibility requirements for business concerns to receive awards under the Small Business Innovation Research Program Lobbied for small business interests. H.R. 3154: To provide incentives for pharmaceutical companies, biotechnology companies, and medical device companies to invest in research and development with respect to antibiotic drugs, antivirals, diagnostic tests, and vaccines that may be used to identify, treat, or prevent an infectious disease, and for other purposes. Lobbied for incentives for the vaccine industry. H.R. 913: To direct the Securities and Exchange Commission to require enchanced disclosures of employee stock options, and to require a study on the economic impact of broad-based employee stock option plans, and for other purposes. Lobbied for the interests of the Biotech Medical Products industry. H.R. 1234: To amend the Internal Revenue Code of 1986 to require greater transparency of corporate tax accounting measures, to facilitate analysis of financial statements, to permit inspection of true corporate tax liability and understand the tax strategies undertaken by corporations, to discourage abusive tax sheltering activities, and to restore investor confidence in publicly traded corporations. Lobbied for the interest of the Biotech Medical products industry. S. 1008: A bill to amend the Internal Revenue Code of 1986 to add meningococcal vaccines to the list of taxable vaccines for purposes of the Vaccine Injury Compensation Trust Fund. Lobbied for incentives for the vaccine industry.

Client expense: Not reported · Firm income: $100,000

Government targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE